Market Overview
Global Intravenous Immunoglobulin (IVIg) market size was valued at USD 10.02 billion in 2024. The market is projected to grow from USD 10.65 billion in 2025 to USD 15.3 billion by 2032, exhibiting a CAGR of 6.4% during the forecast period.
Intravenous Immunoglobulin (IVIg) is a purified antibody solution derived from pooled human plasma, containing concentrated immunoglobulins (primarily IgG) from thousands of healthy donors. This biologic therapy plays a critical role in immune modulation and replacement therapy, primarily used for treating immunodeficiency disorders, autoimmune diseases, and acute infections. n involves complex fractionation and viral inactivation processes to ensure safety and efficacy.
Autoimmune Disease
Acute Infection
Our Key Players
CSL Behring (U.S./Australia)
Grifols, S.A. (Spain)
Baxter International Inc. (U.S.)
Octapharma AG (Switzerland)
Biotest AG (Germany)
Regional Analysis
North America
North America dominates the global IVIg market, accounti approximately 45% of total revenue share. The U.S. drives this to high prevalence of immunodeficiency disorders, robust he infrastructure, and favorable reimbursement policies. The FDA' quality controls ensure product safety, while increasing off-lab neurological disorders expands market potential. However, pressures from bulk procurement programs and limited plasma during COVID-19 created temporary supply constraints. Manu are investing aggressively in plasma collection centers to mee demand, particularly for chronic inflammatory demyelina polyneuropathy (CIDP) treatment - which represents nearly 25 IVIg utilization.
https://www.24lifesciences.com/downloadsample/1083/intravenous-immunoglobulinivig-market
